High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): A phase I trial

References

• Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol 2005;31:845–53.
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89:1142–9.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer – a systematic overview. Rev Recent Clin Trials 2008; 3:204–11.
   PubMedGoogle Scholar
• O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, .Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502–7.
   PubMed Web of Science ®Google Scholar
• Vestermark LW, Jacobsen A, Qvortrup C, Hansen F, Bisgaad C, Baatrup G. . Long-term results of phase II trial of high-dose radiotherapy (60 Gy) and UFT/ l-leukovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 2008;47:428–33.
   PubMed Web of Science ®Google Scholar
• Sadahiro S, Suzuki T, Kameya T, Iwase H, Tajima T, Makuuchi H. A pharmacological study of the weekday-on/weekday-off UFT schedule in colorectal cancer patients. Cancer Chemther Pharmacol 2001;47:447–50.
   Google Scholar
• Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R, Phase I/II trial of capecitabine oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003;21:3098–104.
   PubMed Web of Science ®Google Scholar
• Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G. . A phase I-II studyof weekly oxaliplatin 5-fluorouracil continuous infusion and preoperative radiotherapy in locallyadvanced rectal cancer. Ann Oncol2005;16:1140–6.
   PubMed Web of Science ®Google Scholar
• Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DF, . Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys2000;46:883–8.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Isacsson U, Jung B, Påhlman L. Radiotherapy in addition to radical surgery in rectal cancer: Evidence for a dose-response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;37:281–7.
   PubMed Web of Science ®Google Scholar
• Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: Analysis of phase II/III trials. Br J Radiol 2005;78:934–8.
   PubMed Web of Science ®Google Scholar
• Pfeiffer P. High-dose radiotherapy and concurrent UFT plus l-leukovorin in locally advanced rectal cancer: A phase I trial. Acta Oncol 2005;44:224–9.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Meadows H, Wood W. Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin. Clin Oncol (R Coll Radiol) 2007;19:327–9.
   PubMedGoogle Scholar
• Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomized trials. Ann Oncol 2010;21:1743–50.
   PubMed Web of Science ®Google Scholar
• Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M. . The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:752–;60.
   PubMed Web of Science ®Google Scholar
• Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 2007;183:227–35.
   PubMedGoogle Scholar
• Blomqvist L, Glimelius B. The “good”, the “bad”, and the “ugly” rectal cancers. Acta Oncol 2008;47:5–8.Editorial.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A. Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: Should we be more cautious?Br J Cancer 2006;94:363–71. Review.
   PubMed Web of Science ®Google Scholar
• Valentini V, Glimelius B. Rectal cancer radiotherapy: Towards European consensus. Acta Oncol 2010;49:1206–16.
   PubMed Web of Science ®Google Scholar
• Braendengen M, Tveit KM, Berglund A, Birkemeyer E, Frykholm G, Påhlman L. . Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008;26:3687–94.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Niedzwiecki D, Hollis D. Phase I-II study of preoperative oxaliplatin fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and leukaemia Group B 89901. J Clin Oncol 2006;24:2557–62.
   PubMed Web of Science ®Google Scholar
• Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M. . Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007;25:110–7.
   PubMed Web of Science ®Google Scholar
• Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R . Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99–107.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, . Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 2010;11:835–44.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, .Chemotherapy with preoperative radiotherapy in rectal cancer. New Engl J Med2006;355:1114–23.
   PubMed Web of Science ®Google Scholar
• Gerard J-P, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, . Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006;24:4620–5.
   PubMed Web of Science ®Google Scholar
• Bujko K, Michalski W, Kepka MP, Nowacki MP, Nasierowska-Guttmeier A, Tokar P, .Association between pathologic response in metastatic lymph nodes after preoperative chemotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial. Int J Radiat Oncol Phys 2007;67:369–77.
   PubMed Web of Science ®Google Scholar
• Gerard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, . Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010;28:1638–43.
   PubMed Web of Science ®Google Scholar
• Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, . Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773–80.
   PubMed Web of Science ®Google Scholar
• Gunnlaugsson A, Anderson H, Fernebro E, Kjellen E, Bystrom P, Berglund K, . Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study. Eur J Cancer 2009;45:807–13.
   PubMed Web of Science ®Google Scholar
• Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, . Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase II trial. Lancet Oncol 2010;11:241–8.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, . Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28:859–65.
   PubMed Web of Science ®Google Scholar
• Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, . Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668–74.
   PubMed Web of Science ®Google Scholar